Compare STXS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STXS | IPHA |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.3M | 131.4M |
| IPO Year | 2004 | N/A |
| Metric | STXS | IPHA |
|---|---|---|
| Price | $1.88 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.00 | ★ $5.75 |
| AVG Volume (30 Days) | ★ 364.7K | 118.2K |
| Earning Date | 05-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,346,617.00 | N/A |
| Revenue This Year | $28.22 | $180.36 |
| Revenue Next Year | $30.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.74 | $1.18 |
| 52 Week High | $3.59 | $2.63 |
| Indicator | STXS | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 63.24 |
| Support Level | $1.75 | $1.69 |
| Resistance Level | $1.99 | $2.16 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 47.92 | 47.05 |
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.